Follow-up in aggressive lymphomas

A number of important contributions to the clinical knowledge of aggressive B-cell lymphoma were published over the past year. Among potential practice-changing studies—or those preventing unjustified change, were studies on improved risk classification, dose-dense immunochemotherapy, early autologous stem-cell transplantation, and the first clinical report on the use of immune checkpoint blockade to improve outcome of high-dose therapy.